RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...
L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2 | -0.389105058366 | 51.4 | 52.2 | 50.8 | 282945 | 51.63376895 | DE |
4 | -1 | -1.91570881226 | 52.2 | 54.1 | 49.48 | 288676 | 51.34765516 | DE |
12 | 0.65 | 1.28585558853 | 50.55 | 54.8 | 48.58 | 271999 | 51.81485243 | DE |
26 | 1.78 | 3.60178065561 | 49.42 | 54.8 | 47.38 | 245328 | 51.03646761 | DE |
52 | 4.41 | 9.42509083137 | 46.79 | 54.8 | 46.49 | 238418 | 50.58964977 | DE |
156 | -2.6 | -4.83271375465 | 53.8 | 56.96 | 34.52 | 234939 | 45.6928796 | DE |
260 | 15.72 | 44.3066516347 | 35.48 | 57.9 | 28.26 | 282538 | 44.85442312 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.